Who owns TRAVERE THERAPEUTICS INC (TVTX?

Tip: Access positions for across all investors

Analyze quarterly positions in Travere Therapeutics with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Travere Therapeutics stock

Who bought or sold TRAVERE THERAPEUTICS INC (TVTX this quarter?

Fund or Company Name Shares Held Valued At Change in Shares As Of Actions
Linden Advisors 91M $102M -4% Sep 2025
 View chart
D. E. Shaw & Co 43M $49M -5% Sep 2025
 View chart
Graham Capital Management 22M $25M -47% Sep 2025
 View chart
Advent Capital Management 20M $23M -1% Sep 2025
 View chart
Millennium Management 13M $15M 100% Sep 2025
 View chart
Lord, Abbett & Co 12M $14M 30% Sep 2025
 View chart
Point72 Asset Management 10M $11M 100% Sep 2025
 View chart
Oaktree Capital Management 9.2M $10M 19% Sep 2025
 View chart
Agf Management 8.8M $9.9M -37% Sep 2025
 View chart
Polar Capital Holdings 8.0M $8.9M 167% Sep 2025
 View chart
Affinity Asset Advisors 7.0M $7.9M 0% Sep 2025
 View chart
Henderson Group 6.4M $7.2M -39% Sep 2025
 View chart
Shenkman Capital Management 6.2M $7.2B 11% Sep 2025
 View chart
FMR 3.8M $4.2M -7% Sep 2025
 View chart
BlackRock 3.2M $3.6M 0% Sep 2025
 View chart
Kohlberg Kravis Roberts & Co 2.0M $2.3M 145% Sep 2025
 View chart
New York State Common Retirement Fund 2.0M $2.2M -27% Sep 2025
 View chart
Goldman Sachs Group 1.6M $1.8M 100% Sep 2025
 View chart
Toronto-Dominion Bank 811k $925k -68% Sep 2025
 View chart
Jpmorgan Chase & Co 556k $634k -36% Sep 2025
 View chart
Context Capital Management 46k $53M 22% Sep 2025
 View chart
Branch Banking & Trust Company 41k $46k 0% Sep 2025
 View chart
Stonegate Investment Group 25k $28k 0% Sep 2025
 View chart
Wiley Bros.-aintree Capital 16k $18k 100% Sep 2025
 View chart
Insigneo Advisory Services 13k $15k 0% Sep 2025
 View chart
Wealth Enhancement Advisory Services 10k $12k 0% Sep 2025
 View chart
Northwestern Mutual Wealth Management Company 2.0k $2.3k 100% Sep 2025
 View chart

Who sold out of Travere Therapeutics?

Fund or Company Name Date Sold Shares Held Valued At
Jump Financial Jun 2025 8.0M $7.7M
Lazard Asset Management Jun 2025 500k $477k
Barclays Jun 2025 204k $195k
Leucadia National Corporation Jun 2025 21k $20k